Trial intelligence / Profile preview

Antiviral immune responses in chronic hepatitis C treated with DAA alone or PEG-interferon-based regimens

2015-003024-31Phase 4Completed

Sponsor: Azienda Ospedaliero-Universitaria di Parma
Start: May 2021
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
Countries: 1

Overview

Phase 4 trial of sofosbuvir, ledipasvir, peginterferon alfa-2a and ribavirin in hepatitis C virus infection (2 arms), sponsored by Azienda Ospedaliero-Universitaria di Parma. Primary endpoint: Improvement in HCV-specific CD4 and CD8 T-cell responses. Started May 2021; status: completed.

Drugs

sofosbuvirledipasvirpeginterferon alfa-2aribavirin

Conditions

hepatitis C virus infection

Beyond the preview

Go deeper on 2015-003024-31.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2015-003024-31.